Literature DB >> 33443209

Activation of the Akt1-CREB pathway promotes RNF146 expression to inhibit PARP1-mediated neuronal death.

Hyojung Kim1, Jisoo Park1, Hojin Kang1, Seung Pil Yun2, Yun-Song Lee1, Yun-Il Lee3, Yunjong Lee4,5.   

Abstract

Progressive degeneration of dopaminergic neurons characterizes Parkinson's disease (PD). This neuronal loss occurs through diverse mechanisms, including a form of programmed cell death dependent on poly(ADP-ribose) polymerase-1 (PARP1) called parthanatos. Deficient activity of the kinase Akt1 and aggregation of the protein α-synuclein are also implicated in disease pathogenesis. Here, we found that Akt1 suppressed parthanatos in dopaminergic neurons through a transcriptional mechanism. Overexpressing constitutively active Akt1 in SH-SY5Y cells or culturing cells with chlorogenic acid (a polyphenol found in coffee that activates Akt1) stimulated the CREB-dependent transcriptional activation of the gene encoding the E3 ubiquitin ligase RNF146. RNF146 inhibited PARP1 not through its E3 ligase function but rather by binding to and sequestering PAR, which enhanced the survival of cultured cells exposed to the dopaminergic neuronal toxin 6-OHDA or α-synuclein aggregation. In mice, intraperitoneal administration of chlorogenic acid activated the Akt1-CREB-RNF146 pathway in the brain and provided neuroprotection against both 6-OHDA and combinatorial α-synucleinopathy in an RNF146-dependent manner. Furthermore, dysregulation of the Akt1-CREB pathway was observed in postmortem brain samples from patients with PD. The findings suggest that therapeutic restoration of RNF146 expression, such as by activating the Akt1-CREB pathway, might halt neurodegeneration in PD.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Year:  2020        PMID: 33443209      PMCID: PMC7909008          DOI: 10.1126/scisignal.aax7119

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  40 in total

1.  The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB.

Authors:  J M Wang; J R Chao; W Chen; M L Kuo; J J Yen; H F Yang-Yen
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

Review 2.  Parkinson's disease. First of two parts.

Authors:  A E Lang; A M Lozano
Journal:  N Engl J Med       Date:  1998-10-08       Impact factor: 91.245

3.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.

Authors:  L D Mayo; D B Donner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

4.  Modeling Parkinson's disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain.

Authors:  Poonam Thakur; Ludivine S Breger; Martin Lundblad; Oi Wan Wan; Bengt Mattsson; Kelvin C Luk; Virginia M Y Lee; John Q Trojanowski; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-12       Impact factor: 11.205

5.  Akt signal transduction dysfunction in Parkinson's disease.

Authors:  Suzanne Timmons; Meghan F Coakley; Aileen M Moloney; Cora O' Neill
Journal:  Neurosci Lett       Date:  2009-10-01       Impact factor: 3.046

6.  Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.

Authors:  Daniel Alvarez-Fischer; Carmen Henze; Corinna Strenzke; Jan Westrich; Boris Ferger; Günter U Höglinger; Wolfgang H Oertel; Andreas Hartmann
Journal:  Exp Neurol       Date:  2007-11-01       Impact factor: 5.330

7.  Estrogen receptor activation contributes to RNF146 expression and neuroprotection in Parkinson's disease models.

Authors:  Hyojung Kim; Sangwoo Ham; Joon Yeop Lee; Areum Jo; Gum Hwa Lee; Yun-Song Lee; MyoungLae Cho; Heung-Mook Shin; Donghoon Kim; Olga Pletnikova; Juan C Troncoso; Joo-Ho Shin; Yun-Il Lee; Yunjong Lee
Journal:  Oncotarget       Date:  2017-10-11

8.  Can coffee consumption lower the risk of Alzheimer's disease and Parkinson's disease? A literature review.

Authors:  Regina Wierzejska
Journal:  Arch Med Sci       Date:  2016-11-15       Impact factor: 3.318

9.  Effect of Chlorogenic Acid Supplementation in MPTP-Intoxicated Mouse.

Authors:  Saumitra S Singh; Sachchida N Rai; Hareram Birla; Walia Zahra; Gaurav Kumar; Mallikarjuna R Gedda; Neeraj Tiwari; Ranjana Patnaik; Rakesh K Singh; Surya P Singh
Journal:  Front Pharmacol       Date:  2018-08-06       Impact factor: 5.810

10.  Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss.

Authors:  Yunjong Lee; Senthilkumar S Karuppagounder; Joo-Ho Shin; Yun-Il Lee; Han Seok Ko; Debbie Swing; Haisong Jiang; Sung-Ung Kang; Byoung Dae Lee; Ho Chul Kang; Donghoon Kim; Lino Tessarollo; Valina L Dawson; Ted M Dawson
Journal:  Nat Neurosci       Date:  2013-08-25       Impact factor: 24.884

View more
  4 in total

Review 1.  PARkinson's: From cellular mechanisms to potential therapeutics.

Authors:  Zsofia Lengyel-Zhand; Laura N Puentes; Robert H Mach
Journal:  Pharmacol Ther       Date:  2021-08-12       Impact factor: 12.310

2.  Synthetic Peucedanocoumarin IV Prevents α-Synuclein Neurotoxicity in an Animal Model of Parkinson's Disease.

Authors:  Heejeong Kim; Han-Joo Maeng; Ji Hun Kim; Jin-Ha Yoon; Yohan Oh; Seung-Mann Paek; Yunjong Lee
Journal:  Int J Mol Sci       Date:  2022-08-03       Impact factor: 6.208

3.  Integrated network analysis identifying potential novel drug candidates and targets for Parkinson's disease.

Authors:  Pusheng Quan; Kai Wang; Shi Yan; Shirong Wen; Chengqun Wei; Xinyu Zhang; Jingwei Cao; Lifen Yao
Journal:  Sci Rep       Date:  2021-06-23       Impact factor: 4.379

4.  MOP and NOP receptor interaction: Studies with a dual expression system and bivalent peptide ligands.

Authors:  M F Bird; J McDonald; B Horley; J P O'Doherty; B Fraser; C L Gibson; R Guerrini; G Caló; D G Lambert
Journal:  PLoS One       Date:  2022-01-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.